Online citations, reference lists, and bibliographies.
← Back to Search

Emerging Therapies For Malignant Pleural Mesothelioma

J. Quispel-Janssen, P. Baas
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Malignant pleural mesothelioma continues to challenge clinicians and scientists, since its incidence is rising and prognosis is far from favorable. Currently, the standard treatment consists of a combination of cisplatin and pemetrexed. The role of surgery and multimodality treatment remains controversial, while new treatment approaches, such as immunotherapy and targeted therapies, ad promising and interesting options. This review provides a comprehensive evaluation of emerging therapies and predictive biomarkers that are being tested.
This paper references
Pemetrexed as Second-Line Treatment in Malignant Pleural Mesothelioma after Platinum-Based First-Line Treatment
J. Sørensen (2007)
Modes of resistance to anti-angiogenic therapy
G. Bergers (2008)
IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma (MPM).
G. Zalcman (2010)
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
Intrapleural treatment with recombinant gamma‐interferon in early stage malignant pleural mesothelioma
C. Boutin (1994)
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
G. Scagliotti (2003)
Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM).
A. Nowak (2010)
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2011)
AKT/PKB Signaling: Navigating Downstream
B. Manning (2007)
In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion
P. Szlosarek (2006)
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.
P. Rougier (2000)
Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12.
Irina Caminschi (1999)
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM).
A. Dudek (2010)
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy.
H. Gamm (1991)
A systematic review of lung-sparing extirpative surgery for pleural mesothelioma
Elaine S Teh (2011)
Pemetrexed Disodium or Observation in Treating Patients With Malignant Pleural Mesothelioma Without Progressive Disease After First - Line Chemotherapy
F Vandermeers
Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.
G. Ak (2010)
Phase II Study of Gemcitabine Plus Docetaxel as Second-Line Treatment in Malignant Pleural Mesothelioma: A Single Institution Study
Ioannis S Tourkantonis (2011)
Malignant pleural mesothelioma: staging systems.
P. V. Schil (2005)
IFCTGFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma
G Zalcman (2010)
Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
C. Lee (2009)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma.
G. Zalcman (2010)
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
J. van Haarst (2002)
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer
B. Delage (2010)
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
S. Kalmadi (2008)
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
J. Hegmans (2010)
Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
F. Curnis (2000)
Effect of interferon-alpha 2a on malignant mesothelioma.
T. Christmas (1993)
Activation of the PI3K-AKT pathway in human malignant mesothelioma cells.
Y. Suzuki (2009)
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
Pleomorphic Epithelioid Diffuse Malignant Pleural Mesothelioma: A Clinicopathological Review and Conceptual Proposal to Reclassify as Biphasic or Sarcomatoid Mesothelioma
Kyuichi Kadota (2011)
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
V. Gregorc (2010)
A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma
Kyuichi Kadota (2012)
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF‐1 and ‐2, and TGF β expression
S. Kumar-Singh (1999)
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
L. Righi (2010)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
W. Kelly (2005)
Efficacy and safety of first‐ or second‐line irinotecan, cisplatin, and mitomycin in mesothelioma
D. Fennell (2007)
Phase I trial of recombinant human tumour necrosis factor α in patients with advanced malignancy
H. Gamm (1991)
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion*
A. Rump (2004)
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
R. Pirker (2012)
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
G. Pasello (2011)
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group.
C. Belani (2004)
Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion.
P. Astoul (1993)
Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells.
J. Hegmans (2005)
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
D. P. M. van den Bogaert (2006)
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
Angiogenesis is an independent prognostic factor in malignant mesothelioma
J. Edwards (2001)
The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study
T. Treasure (2009)
A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy.
P. Baas (2011)
Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
R. Hassan (2010)
Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma
J. Cortese (2006)
A Clinical Trial of ADI - PEG 20 TM in Patients With Malignant Pleural Mesothelioma ( ADAM )
JF Cortese
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
G. Shapiro (2011)
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers
R. Hassan (2007)
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
T. Frauenfelder (2011)
VANTAGE 014: Vorinostat (V) in Patients With Advanced Malignant Pleural Mesothelioma (MPM) who Have Failed Prior Pemetrexed and Either Cisplatin or Carboplatin Therapy: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial
L. Krug (2011)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
IL-2 Intratumoral Immunotherapy Enhances CD8+ T Cells That Mediate Destruction of Tumor Cells and Tumor-Associated Vasculature: A Novel Mechanism for IL-2 1
C. Jackaman (2003)
Valproate, in Combination with Pemetrexed and Cisplatin, Provides Additional Efficacy to the Treatment of Malignant Mesothelioma
F. Vandermeers (2009)
Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
T. Karrison (2007)
Thalidomide in patients with malignant pleural mesothelioma.
P. Baas (2005)
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
Effect of Interferon-α2a Malignant Mesothelioma
T. Christmas (1993)
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
S. Laurie (2011)
What's the place of immunotherapy in malignant mesothelioma treatments?
M. Grégoire (2010)
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
D. Jackman (2008)
Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography Scans
F. Liu (2010)
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study
A. Scherpereel (2010)
Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
S. Ramalingam (2009)
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy
M. Brevet (2011)
Cediranib (C) in patients (pts) with malignant mesothelioma (MM): A phase II trial of The University of Chicago Phase II Consortium.
N. Campbell (2011)
Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single‐agent 5‐fluorouracil and adriamycin
V. Harvey (1984)
A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.
D. Sterman (2011)
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
C. Manegold (2005)
A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
S. Dubey (2010)
A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL
J. Symanowski (2009)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar